<p>Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles</p>

• DOI: 10.2147/cmar.s249838
• Publication Date: 2020-06-28T22:44:34Z
• Authors: Yuxin Zhong; Jing Zhang; Xiaofeng Bai; Yuemin Sun; Hao Liu; Shuai Ma; Yang Li; Wenzhe Kang; Fuhai Ma; Weikun Li; Yantao Tian
• Keywords: Hyperthermic Intraperitoneal Chemotherapy

This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer.Advanced cancer patients who underwent radical resection and/or HIPEC were systematically reviewed our department from January 2016 June 2017. All enrolled grouped either or non-HIPEC groups. Clinical data collected analyzed.A total 129 with 61 cases group 68 group. The two groups well balanced terms clinical characteristics. In group, three suffered leakage duodenal stump anastomosis, one abnormal bleeding found have routine blood tests; no significant difference adverse events between groups, however, was noted (p > 0.05) most recovered uneventfully. During follow-up, peritoneal recurrence significantly less among = 0.029), only suffering recurrence, as compared 12 patients. addition, estimated illness-specific 3-year disease-free survival rate higher (89.4% vs.73.9%; p 0.031).Lobaplatin is safe after treatment by can effectively improve survival.